News and Treatment Updates

Abstract The Dedicator of Cytokinesis1 (DOCK1) has been implicated in solid tumors; however, its precise role and therapeutic potential in acute myeloid leukemia (AML) remain largely unexplored. Here we investigated the prognostic significance and functional roles of DOCK1 in AML…

Haploidentical bone marrow transplantation (haplo-BMT) with post-transplant cyclophosphamide (PT-Cy) has become an established alternative for patients lacking HLA-matched donors, with outcomes comparable to those of matched-sibling and unrelated-donor transplants [1]. While CD34…

Abstract Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematologic malignancies, yet its application to acute myeloid leukemia (AML) remains challenging due to the scarcity of disease-specific antigens. The identification of a highly selective…

To fully appreciate how quickly molecular analysis has transformed evaluation and treatment decisions in acute myeloid leukemia (AML), we need look no further than the seminal article by JP Patel et al. published in 2012 in The New England Journal of Medicine concerning the…

Highlight The 10-year incidence of non-cutaneous SM (6.8%) confirms its impact on late NRM. SM subtype distribution and timing vary by transplant: t-MDS/AML after auto-HCT, PTLD early after allo-HCT. PTLD declined markedly, nearly disappearing in the PTCy era with less ATG/Cord…

Key Points: Many patients and caregivers associate early palliative care (EPC) with hospice or death, a misperception that may persist even after gaining a better understanding of the role of EPC and may prevent them from experiencing the benefits of EPC. Cultural or religious…

Abstract Background ASXL1 mutations (ASXL1MUT) are common in acute myeloid leukemia (AML) and have historically conferred an adverse prognosis with intensive chemotherapy. Given the increasing use of venetoclax (VEN)-based lower intensity therapy (LIT), the European LeukemiaNet…

Abstract Objective: To evaluate the efficacy and prognostic factors of haploidentical haematopoietic stem cell transplantation (haplo-HSCT) for paroxysmal nocturnal haemoglobinuria (PNH). Methods: We retrospectively analyzed 36 PNH patients (2 classic PNH, 34 AA-PNH syndrome)…

Summary This UK-based retrospective analysis describes real-world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast-phase (BP, n = 106) ‘Philadelphia-negative’ myeloproliferative neoplasms (MPN-AP/BP) diagnosed between 2013 and 2025. Median…

Abstract Developing chimeric antigen receptor (CAR) T cells for acute myeloid leukemia (AML) has been challenging due to a lack of known AML-associated antigens that spare normal hematopoietic precursor cells. Here we reasoned that donor autoantibodies from AML recipients cured…